Free Trial

Grifols (GRFS) Competitors

Grifols logo
$9.07 -0.07 (-0.71%)
As of 07/3/2025 01:04 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

GRFS vs. TEVA, SMMT, ITCI, GMAB, RDY, ASND, VTRS, QGEN, MRNA, and BPMC

Should you be buying Grifols stock or one of its competitors? The main competitors of Grifols include Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Viatris (VTRS), Qiagen (QGEN), Moderna (MRNA), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical products" industry.

Grifols vs. Its Competitors

Teva Pharmaceutical Industries (NYSE:TEVA) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations, institutional ownership and media sentiment.

54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are held by company insiders. Comparatively, 0.2% of Grifols shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Teva Pharmaceutical Industries had 13 more articles in the media than Grifols. MarketBeat recorded 14 mentions for Teva Pharmaceutical Industries and 1 mentions for Grifols. Teva Pharmaceutical Industries' average media sentiment score of 1.15 beat Grifols' score of -0.13 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Teva Pharmaceutical Industries
9 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Grifols
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Grifols has a net margin of 0.00% compared to Teva Pharmaceutical Industries' net margin of -7.74%. Teva Pharmaceutical Industries' return on equity of 45.44% beat Grifols' return on equity.

Company Net Margins Return on Equity Return on Assets
Teva Pharmaceutical Industries-7.74% 45.44% 6.95%
Grifols N/A N/A N/A

Grifols has lower revenue, but higher earnings than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Teva Pharmaceutical Industries$16.54B1.18-$1.64B-$1.15-14.83
Grifols$7.81B0.80$169.80M$1.177.76

Teva Pharmaceutical Industries has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500. Comparatively, Grifols has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500.

Teva Pharmaceutical Industries presently has a consensus target price of $24.13, indicating a potential upside of 41.50%. Grifols has a consensus target price of $10.30, indicating a potential upside of 13.50%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher possible upside, research analysts clearly believe Teva Pharmaceutical Industries is more favorable than Grifols.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Teva Pharmaceutical Industries
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
2 Strong Buy rating(s)
3.22
Grifols
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
3.00

Summary

Teva Pharmaceutical Industries beats Grifols on 13 of the 17 factors compared between the two stocks.

Get Grifols News Delivered to You Automatically

Sign up to receive the latest news and ratings for GRFS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GRFS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GRFS vs. The Competition

MetricGrifolsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$6.24B$2.43B$5.53B$9.05B
Dividend YieldN/A1.78%5.24%4.03%
P/E Ratio7.768.9827.5220.22
Price / Sales0.80682.84421.02118.64
Price / Cash9.70158.5936.8958.07
Price / Book0.674.588.045.67
Net Income$169.80M$31.34M$3.18B$249.13M
7 Day Performance2.43%3.25%2.90%3.28%
1 Month Performance4.07%7.08%3.70%5.55%
1 Year Performance28.91%0.17%36.15%21.12%

Grifols Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GRFS
Grifols
4.0538 of 5 stars
$9.08
-0.7%
$10.30
+13.5%
+36.7%$6.24B$7.81B7.7623,822
TEVA
Teva Pharmaceutical Industries
4.2262 of 5 stars
$16.96
+0.1%
$24.44
+44.1%
+1.4%$19.45B$16.54B-14.7536,830
SMMT
Summit Therapeutics
2.528 of 5 stars
$20.39
-0.8%
$35.09
+72.1%
+253.3%$15.14B$700K-59.97110Trending News
Analyst Forecast
Options Volume
ITCI
Intra-Cellular Therapies
0.982 of 5 stars
$131.87
flat
$109.70
-16.8%
N/A$14.05B$680.50M-151.57560
GMAB
Genmab A/S
3.5747 of 5 stars
$20.68
-2.3%
$39.17
+89.4%
-18.8%$13.26B$3.12B11.752,682High Trading Volume
RDY
Dr. Reddy's Laboratories
2.4474 of 5 stars
$15.31
+0.5%
$16.95
+10.7%
-0.9%$12.78B$3.81B23.2027,811
ASND
Ascendis Pharma A/S
3.6614 of 5 stars
$175.78
-0.6%
$220.67
+25.5%
+29.7%$10.75B$393.54M-27.991,017Analyst Forecast
VTRS
Viatris
3.847 of 5 stars
$8.85
-0.2%
$10.40
+17.5%
-10.9%$10.39B$14.74B-2.7932,000
QGEN
Qiagen
4.0422 of 5 stars
$46.72
-0.1%
$47.74
+2.2%
+22.5%$10.39B$2.00B117.145,765Dividend Announcement
MRNA
Moderna
4.3794 of 5 stars
$25.67
-0.9%
$46.61
+81.6%
-73.7%$9.93B$3.14B-2.945,800Options Volume
BPMC
Blueprint Medicines
1.7373 of 5 stars
$128.40
+0.2%
$128.06
-0.3%
+17.6%$8.29B$508.82M-51.98640High Trading Volume

Related Companies and Tools


This page (NASDAQ:GRFS) was last updated on 7/5/2025 by MarketBeat.com Staff
From Our Partners